Lirum Therapeutics, Inc. (LRTX)

Lirum Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	4.01	4.01	0.17
Cash & Cash Equivalents	4.01	4.01	0.17
Cash Growth	-	2198.57%	-
Other Current Assets	0.56	0.56	0.24
Total Current Assets	4.57	4.57	0.41
Total Assets	4.57	4.57	0.41
Accounts Payable	0.8	0.8	0.23
Other Current Liabilities	1.38	1.38	1.6
Total Current Liabilities	2.18	2.18	1.83
Long-Term Debt	-	-	0.5
Total Long-Term Liabilities	0	0	0.5
Total Liabilities	2.18	2.18	2.33
Total Debt	0	0	0.5
Retained Earnings	-4.15	-4.15	-1.95
Shareholders' Equity	2.39	2.39	-1.92
Net Cash / Debt	4.01	4.01	-0.33
Working Capital	2.39	2.39	-1.42

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).